Aktienanalyse zu Exicure Inc (XCUR)XCURExicure Inc

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Exicure Inc is not a good buy right now due to its current price of $0.91, a significant decline of 83.61% year-to-date, and a concerning RSI of 41.379 indicating bearish momentum. Additionally, insider selling has increased by 106.79% over the last month, signaling a lack of confidence from those closest to the company. The main risk is the potential delisting from Nasdaq due to failing to meet the minimum stockholders' equity requirement of $2.5 million, as the latest reported equity stands at only $2.1 million.

1 analysts cover XCUR: 1 rate it Buy, 0 Hold and 0 Sell.